Fatty Liver, Insulin Resistance, and Obesity: Relationships With Increase in Coronary Artery Calcium Over Time

Clinical Cardiology

Volumn 39, Issue 6, 2016, Pages 321-328

  Sung, Ki Chul ^a   Ryu, Seungho ^a   Lee, Jong Young ^a   Lee, Sung Ho ^a   Cheong, Eun Sun ^a   Wild, Sarah H ^b   Byrne, Christopher D ^c  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c and University of Bristol   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; INSULIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIAC IMAGING; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY CALCIUM SCORE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; ECHOGRAPHY; FATTY LIVER; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; OBESITY; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; SOUTH KOREA;

EID: 84976336377     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22529     Document Type: Article

References (35)

1. Budoff MJ, Achenbach S, Blumenthal RS, et al. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation. 2006;114:1761–1791.
2. Kantor B, Nagel E, Schoenhagen P, et al. Coronary computed tomography and magnetic resonance imaging. Curr Probl Cardiol. 2009;34:145–217.
3. Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358:1336–1345.
4. Zeb I, Budoff M. Coronary artery calcium screening: does it perform better than other cardiovascular risk stratification tools? Int J Mol Sci. 2015;16:6606–6620.
5. Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54:1082–1090.
6. Sung KC, Wild SH, Kwag HJ, et al. Fatty liver, insulin resistance, and features of metabolic syndrome: relationships with coronary artery calcium in 10 153 people. Diabetes Care. 2012;35:2359–2364.
7. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113–121.
8. Dunn W, Xu R, Wingard DL, et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol. 2008;103:2263–2271.
9. Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–873.
10. Fraser A, Harris R, Sattar N, et al. γ-Glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis [published correction appears in Arterioscler Thromb Vasc Biol. 2008;28:e14. Arterioscler Thromb Vasc Biol. 2007;27:2729–2735.
11. Hamaguchi M, Kojima T, Takeda N, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 2007;13:1579–1584.
12. Haring R, Wallaschofski H, Nauck M, et al. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum γ-glutamyl transpeptidase levels. Hepatology. 2009;50:1403–1411.
13. Lee DH, Silventoinen K, Hu G, et al. Serum γ-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28 838 middle-aged men and women. Eur Heart J. 2006;27:2170–2176.
14. Ruttmann E, Brant LJ, Concin H, et al. γ-Glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163 944 Austrian adults. Circulation. 2005;112:2130–2137.
15. Schindhelm RK, Dekker JM, Nijpels G, et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis. 2007;191:391–396.
16. Söderberg C, Stål P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;51:595–602.
17. Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care. 2007;30:2119–2121.
18. Yun KE, Shin CY, Yoon YS, et al. Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans. Atherosclerosis. 2009;205:533–537.
19. Bhatia LS, Curzen NP, Calder PC, et al. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J. 2012;33:1190–1200.
20. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:1341–1350.
21. Sung KC, Jeong WS, Wild SH, et al. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care. 2012;35:717–722.
22. Blaha MJ, DeFilippis AP, Rivera JJ, et al. The relationship between insulin resistance and incidence and progression of coronary artery calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care. 2011;34:749–751.
23. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–1645.
24. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999;16:442–443.
25. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed). 1986;292:13–15.
26. Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15:827–832.
27. Berry JD, Liu K, Folsom AR, et al. Prevalence and progression of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated risk for cardiovascular disease: the coronary artery risk development in young adults study and multi-ethnic study of atherosclerosis. Circulation. 2009;119:382–389.
28. Raggi P, Cooil B, Shaw LJ, et al. Progression of coronary calcium on serial electron beam tomographic scanning is greater in patients with future myocardial infarction. Am J Cardiol. 2003;92:827–829.
29. Budoff MJ, Hokanson JE, Nasir K, et al. Progression of coronary artery calcium predicts all-cause mortality. JACC Cardiovasc Imaging. 2010;3:1229–1236.
30. Al Rifai M, McEvoy JW, Nasir K, et al. Traditional cardiovascular disease risk factors associated with one-year all-cause mortality among those with coronary artery calcium scores ≥400. Atherosclerosis. 2015;241:495–497.
31. Puri R, Nicholls SJ, Shao M, et al. Impact of statins on serial coronary calcification during atheroma progression and regression. J Am Coll Cardiol. 2015;65:1273–1282.
32. Byrne CD, Olufadi R, Bruce KD, et al. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond). 2009;116:539–564.
33. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 suppl):S47–S64.
34. Tailleux A, Wouters K, Staels B. Roles of PPARs in NAFLD: potential therapeutic targets. Biochim Biophys Acta. 2012; 1821:809–818.
35. Kleiner DE, Brunt EM, Van Natta M, et al; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321.